News & Analysis on Clinical Trial Services & Contract Research And Development
Japanese glass and chemical company Central Glass has found a swift route into the contract manufacturing market for active pharmaceutical ingredients (APIs) in Europe via the purchase of Girindus' facility in Halle-Kuensebeck.
The pharmaceutical industry could save millions by adopting new crystal monitoring technology, according to research published in Crystal Growth and Design.
Bristol-Myers Squibb (BMS) has recruited IBM in its latest round of outsourcing, granting the IT giant a $324m business process outsourcing (BPO) contract.
Contract pharmaceutical services supplier Arch Pharmalabs has purchased a 70 per cent stake in fellow India-based active pharmaceutical supplier (API) Benzochem Lifesciences for around Rs 1bn ($23m), strengthening its position in the cancer drug market.
The impending ban on albuterol inhalers that use chlorofluorocarbon (CFC) propellants will see branded hydrofluoroalkane (HFA)-based products completely dominate the US market as, to date, no generic HFA albuterol has been developed.
Russia has witnessed a drop in generating new business activity on the clinical trials scene over the past year, but has been increasing its own activity in this field.